• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Summit Therapeu ADR (NQ: SMMT )

    11.60 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1
    Open 11.60
    Bid (Size) 11.00 (3)
    Ask (Size) 11.90 (11)
    Prev. Close 11.60
    Today's Range 11.60 - 11.60
    52wk Range 1.520 - 11.90
    Shares Outstanding 97,381,774
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
    From Summit Therapeutics Inc.
    Via Business Wire
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Summit Therapeutics Inc.
    Via Business Wire

    Performance

    YTD
    +339.39%
    +339.39%
    1 Month
    +32.04%
    +32.04%
    3 Month
    +155.51%
    +155.51%
    6 Month
    +210.16%
    +210.16%
    1 Year
    +504.17%
    +504.17%

    More News

    Read More
    SMMT Stock Earnings: Summit Therapeutics Beats EPS for Q2 2024
    Via InvestorPlace
    Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024
    From Summit Therapeutics Inc.
    Via Business Wire
    Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024
    From Summit Therapeutics Inc.
    Via Business Wire
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab
    From Summit Therapeutics Inc.
    Via Business Wire
    Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs
    Via Investor's Business Daily
    Topics Government
    Exposures Political
    IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
    Via Benzinga
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Summit Therapeutics Inc.
    Via Business Wire
    7 Top Stocks Under $10: June 2024 Edition
    Via InvestorPlace
    3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
    Via The Motley Fool
    Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
    Via Talk Markets
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Five Below Posts Weak Q1 Results, Joins Sprinklr, Dorian LPG And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    Why Summit Therapeutics Stock Is Trading 8% Higher Monday
    Via Benzinga
    Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
    From Summit Therapeutics Inc.
    Via Business Wire
    Day Trading During A Slow Holiday Week
    Via Talk Markets
    Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
    Via Talk Markets
    Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
    From Summit Therapeutics Inc.
    Via Business Wire
    Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
    From Summit Therapeutics Inc.
    Via Business Wire
    Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.